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During canine leishmaniasis (CanL) due to Leishmania infantum, high levels of antibodies production are associated with
the presence of various clinical signs, because of the deposition of soluble immune complexes in organs and tissues. The
immunofluorescence antibody test (IFAT) is one of the most commonly used techniques for detection of anti-Leishmania
antibodies. The purpose of this study was to assess whether there is a correlation between clinical signs and IFAT titers in dogs
naturally infected with Leishmania. A retrospective study was performed on medical records of 49 dogs diagnosed with CanL.
Information extracted from the medical records of each dog with CanL was clinical score, IFAT titer, serum total protein (TP),
gamma globulin (IgG) and creatinine concentration, and protein creatinine ratio in urine sample (UP/UC) at each follow-up
examination. Results show that dogs with highest IFAT titers recorded had higher mean clinical scores indicating a positive
relationship (푃 < 0.0001) between anti-Leishmania antibodies (IgG) and clinical manifestations, which becomes more evident in
severe clinical forms of canine leishmaniasis. Higher TP and IgG serum concentrations were recorded in dogs with higher clinical
scores. Significant association was observed between UP/UC and the IFAT titer (푃 = 0.004).
1. Introduction
Leishmaniasis due to Leishmania spp infection has a wide
distribution in four continents and affects mainly dogs,
humans, and rodents. Dogs are the main reservoir for
zoonotic human visceral infection caused by L. infantum
parasite and play a pivotal role in the transmission of the
disease, via phlebotomine sandflies (Phlebotomus spp. and
Lutzomyia spp. in the Old and New World), to people [1].
Canine leishmaniasis (CanL) due to L. infantum is a life-
threatening disease, which may be fatal before treatment
can be instigated [1]. Clinical presentations of CanL range
from subclinical/asymptomatic to full-blown disease, with
variable laboratory findings depending on the host’s immune
response [2]. When the immune response is mediated by
Th2 lymphocytes, IL-4 secretors antibody production is high
and this is associated with severe clinical manifestations [3].
Many studies [4, 5] report that high levels of antibodies
production are associated with the presence of clinical signs
such as epistaxis, proteinuria, polyuria, polydipsia, uveitis,
and skin ulcers because of the deposition of soluble immune
complexes in organs and tissues [3, 6]. Several authors [5,
7, 8] evaluated the profile of anti-Leishmania antibodies in
dogs with different clinical forms of visceral leishmaniasis
using methods not easily obtainable in clinical practice.
The immunofluorescence antibody test (IFAT) is one of the
most commonly used techniques [9] for detection of anti-
Leishmania antibodies and is recommended by World Orga-
nization for Animal Health (OIE) as the reference serological
method [10]. High antibody levels are associated with high
levels of parasitism [2] and provide a definitive diagnosis of
CanL [9].
The purpose of this study was to assess whether there is
a correlation between clinical signs and IFAT titers in dogs,
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naturally infected with L. infantum, to determine whether
IFAT titers could be used as a predictor of the severity of
clinical disease.
2. Materials and Methods
A retrospective study was performed. The medical records
of 131 dogs diagnosed with CanL that were presented to the
Teaching Animal Hospital of the Department of Health, Ani-
mal Science and Food Safety of University of Milan between
2008 and 2013were reviewed.The following inclusion criteria
were used: clinical diagnosis of CanL confirmed by positive
serology for Leishmania infantumusing IFAT and cytological
identification of Leishmania amastigotes or detection of para-
site DNA using polymerase chain reaction (PCR). IgG anti-L.
infantum antibodies were measured by IFAT according to the
recommendations of OIE [10] using MHOM/IT/80/IPT1 as a
whole-parasite antigen fixed onmultispot slides (BioMerieux
Spa, Florence, Italy) and fluorescently labeled anticanine
gamma globulin (Sigma Aldrich, Milan, Italy) as conjugate.
Positive sera were serially diluted and tested to establish the
maximumreaction titer, starting at a dilution of 1 : 40. Positive
and negative controls were included on each slide.
The real-time PCR analysis of whole blood or samples
from lymph node aspiration was performed using the Illustra
Blood genomicPrep Mini Spin kit (GE Healthcare, Milan,
Italy) following the manufacturer’s instructions. The target
for amplification was a 116-bp fragment in the constant
region of the kDNA minicircle of L. infantum. This is one
of the kDNA minicircle families that are used to identify
the Leishmania genus. The primers used were QLK2-UP
5耠-GGCGTTCTGCGAAAACCG-3耠 and QLK2-DOWN 5耠-
AAAATGGCATTTTCGGGCC-3耠; the TaqMan probes were
Q Leish Probe 2 and 5耠-FAM TGGGTGCAGAAATCCCGT-
TCA-3耠-Black Hole.
At the moment of the diagnosis and at each follow-
up a complete physical examination was performed on
all dogs after which clinical assessment of the severity of
signs attributable to Leishmania infection (scored on a scale
from 0 to 3) was made (Table 1). During each follow-up a
complete blood count, hematological and serum biochemical
examinations (including the determination of total protein
and serum electrophoretic pattern), and urine examination
were performed.
All dogs in which concomitant infectious diseases (e.g.,
babesiosis, ehrlichiosis, and dirofilariasis) were diagnosed
by parasitological or/and serological examinations were
excluded.
2.1. Medical Records Review. Information extracted from the
medical records of each dog at each follow-up examination
with CanL was clinical score, IFAT titer, serum total protein
(TP), gamma globulin (IgG) and creatinine concentration,
and protein creatinine ratio in urine sample (UP/UC).
A total of 49/131dogs (37.4%)met the criteria for inclusion
in the study. Ages of the dogs ranged from 0.7 to 14 years
with a median age of 6 years. Twenty-eight were intact males
and 21 were females (10 neutered); 21 were X-breeds and 28
were purebreds. A mean of 13.9 (min 2-max 18) follow-up
examinations was done for each dog.
To assess the relationship between the IFAT titer and
the parameters considered, that is, clinical score, serum
total protein, IgG and creatinine concentration, and UP/UC,
the recorded values from each follow-up examination were
divided into 9 groups according to the IFATvalue (1 : 40, 1 : 80,
1 : 160, 1 : 320, 1 : 640, 1 : 1240, 1 : 2560, 1 : 5120, and 1 : 10240)
regardless of the subject to which they belonged.
2.2. Statistical Analysis. Mean, standard deviation, median
of clinical score value (CS), TP, IgG, creatinine (Cr), and
UP/UC were calculated after calculating normal distribution
of parametric data using the D’Agostino-Pearson test. Mann-
Whitney was used for independent samples tests to assess
any statistically significant difference in the mean of clinical
scores and PT, IgG, creatinine, and UP/UC of dogs with
different IFAT titers (40 versus 80, 80 versus 160, 160 versus
320, etc.).
Spearman’s coefficient of rank correlation (rho) was used
to evaluate the degree of association between themean values
of variables CS, PT, IgG, Cr, and UP/UC and IFAT titer.
For all tests significance was set as 푃 < 0.05. Statistical
analyses were performed using commercial software (Med-
Calc Software v.13.0.0.0, Mariakerke, Belgium).
3. Results
Comparison of mean values and standard deviation of clini-
cal score, total protein, IgG, creatinine, and UP/UC in the 9
groups based on the IFAT titer are reported in Table 2.
The significance and the degree of association between
the mean values of all variables, IFAT titer, clinical score, TP,
IgG, creatinine, and UP/UC are reported in Table 3.
4. Discussion
Detection of specific serum antibodies is widely used in
the diagnosis of CanL [11]. Treatment of sick dogs is often
accompanied by a decrease in the specific antibody levels
[9, 11, 12]. However, in other cases clinical improvement has
not been associated with a decrease in the titer of specific
antibodies [13].
This study was conducted to investigate whether there
was a correlation between the IFAT titer and the clinical score
in dogs with CanL.
Higher clinical score values were detected in dogs with
higher IFAT titers and a significant level of association
between IFAT titer and clinical score (푃 < 0.0001) was found.
The dogwith themaximum clinical score (score = 30) had the
highest IFAT titer (1 : 10240).
There was a similar trend in serum total protein and
IgG concentrations: higher TP and IgG concentrations were
recorded in dogs with higher clinical scores. As expected,
the IFAT titer was also related to TP and IgG (푃 < 0.0001).
Similar results were found by Corona et al. [3] who reported
that the changes in quantitative determination of specific
antibodies paralleled those of total protein and IgG fractions.
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Table 1: Score for clinical parameters (on a scale from 0 to 3, maximum total score 87) in dogs with CanL.
Clinical sign 0 1 2 3
Appetite Normal Slight decrease Moderate decrease Anorexia
Mentation Normal Slight depression Depression Prostration
Exercise intolerance No Slight Moderate Refusal to move
Weight loss No Slight Moderate Severe
Polyuria No Slight Moderate Severe
Polydipsia No Slight Moderate Severe
UP/UC No <1 >1 < 2 >2
Localized muscle
atrophy (temporal
muscles)
No Slight Moderate Severe
Generalized muscle
atrophy No Slight Moderate Severe
Lymphadenomegaly No 1-2 nodes >2 < 4 nodes Generalized
Splenomegaly No Yes
Conjunctivitis and/or
blepharitis No Unilateral and slight Bilateral or unilateral severe Bilateral and severe
Uveitis and/or
keratitis No Unilateral and slight Bilateral or unilateral severe Bilateral and severe
Pale mucous
membranes No Slight Moderate Severe
Epistaxis Neverpresented Sporadic Frequent Persistent
Mouth ulcers or
nodules No
1 or 2 small ulcers or
nodules >2 small ulcers or nodules >1/4 of oral cavity coveredby ulcers or nodules
Vomiting No Sporadic Frequent Frequent with blood
Diarrhea No Sporadic Frequent Persistent
Lameness No Sporadic Frequent Constant
Erythema No <10% body surface or slightgeneralized erythema 10–25% body surface ormoderate generalizederythema >25% body surface
Dry exfoliative
dermatitis No
<10% body surface or slight
generalized erythema
10–25% body surface or
moderate generalized
erythema
>25% body surface
Ulcerative dermatitis No 1-2 ulcers 3–5 ulcers >5 ulcers
Nodular dermatitis No 1-2 nodules 3–5 nodules >5 nodules
Sterile pustular
dermatitis No 1-2 pustules 3–5 pustules >5 pustules
Alopecia No <10% body surface 10–25% body surfaceerythema >25% body surface
Altered pigmentation No Localized Multifocal Generalized
Hyperkeratosis truffle
and pads No Slight Moderate Severe
Generalized
hyperkeratosis No Slight Moderate Severe
Onychogryphosis No Slight Moderate Severe
It is well known that the clinical manifestations of CanL
are the consequence of the host immune response and are
associated with deposition of soluble immune complexes
in different tissues [9]. In infected dogs, the defective cell-
mediated immunity results in uncontrolled multiplication
of the parasite and subsequent polyclonal, and sometimes
monoclonal, activation of B cells with overproduction of
immunoglobulins. These antibodies do not provide protec-
tion for the host but result in the formation of immune
complexes that can damage a variety of tissues and organs.
Several studies have described the levels of specific Leish-
mania IgG subclasses (IgG1, IgG2, IgM, IgA, and IgE)
in sick, asymptomatic, and treated dogs, sometimes with
conflicting results [4, 5, 7, 8]. Solano-Gallego et al. [14]
determined the level of Leishmania-specific total IgG (IgG),
IgG1, and IgG2 antibody responses in the sera of a wide
range of canine populations: symptomatic and asymptomatic
dogs from endemic areas and naturally and experimentally
infected dogs, showing that clinical signs are directly related
to IgG1 and IgG2 and that IgG2 concentrations are more
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Table 2: Mean value and standard deviation of clinical score, total protein, IgG, creatinine, and UP/UC in the 9 groups of dogs categorized
according to IFAT titer.푁∘ dogs IFAT titer Mean clinicalscore (±SD) Mean totalprotein(±SD) g/dL Mean IgG(±SD) % Mean creatinine(±SD) mg/dL Mean UP/UC(±SD)
19 1 : 40 0.94 ± 0.97 6.72 ± 0.69 10.71 ± 3.23 1.15 ± 0.35 0.29 ± 0.68
46 1 : 80 0.98 ± 1.2 6.82 ± 0.66 11.67 ± 3.5 1.1 ± 0.38 0.84 ± 1.48
54 1 : 160 1.48 ± 2.02 6.97 ± 0.7 13.44 ± 3.81 0.94 ± 0.4 0.58 ± 1.56
48 1 : 320 2.65 ± 2.89 7.27 ± 0.88 17.85 ± 7.4 0.94 ± 0.31 0.16 ± 0.27
37 1 : 640 4.32 ± 3.48 7.94 ± 1.28 25.79 ± 12.18 1.05 ± 0.7 0.85 ± 2
19 1 : 1280 5.10 ± 4.71 8.52 ± 1.43 31.69 ± 13.03 1.26 ± 1 1.34 ± 2.27
9 1 : 2560 4.78 ± 3 9.38 ± 1.39 44.37 ± 9.41 1.62 ± 1.42 0.17 ± 0.06
2 1 : 5120 16 ± 9.9 10.75 ± 0.07 64.65 ± 17 0.95 ± 0.35 —
1 1 : 10240 30 10.7 53.2 0.7 —
Table 3: 푃 and rho values of IFAT titer and clinical score, total
protein, gamma globulin, creatinine, and UP/UC. 푃 value shows
the level of significance of the association and rho the degree of
association between the mean values of variables.푃 Rho
IFAT <0.0001 0.454Clinical score
IFAT <0.0001 0.532Total protein
IFAT <0.0001 0.728Gamma globulin
IFAT 0.0786 −0.117Creatinine
IFAT 0.004 0.222UP/UC
Total Protein <0.0001 0.436Clinical score
Total protein <0.0001 0.678Gamma globulin
Total protein 0.0037 −0.193Creatinine
Total Protein 0.0307 0.168UP/UC
Gammaglobulin <0.0001 0.391Clinical score
Gammaglobulin 0.95 0.0042Creatinine
Gammaglobulin 0.0243 0.175UP/UC
Creatinine 0.0148 −0.162Clinical score
Creatinine 0.8171 0.0181UP/UC
UP/UC 0.0035 0.225Clinical score
strongly correlated with clinical illness than IgG1. De Freitas
et al. [5] investigated the profile of anti-Leishmania antibodies
in different clinical forms ofCanL andobserved that IgG2 and
IgM were positively correlated with clinical signs while total
IgG, IgG1, and IgA were negatively correlated. The varying
immune response of infected animals may account for the
conflicting results reported by various authors [4].The IFAT
test is one of the recommendedmethods for the evaluation of
anti-Leishmania antibodies [15] and is widely used in clinical
practice while the antibody assay of each class of antibodies
is not routinely practiced. Our results are in accordance
with the findings of Almeida et al. [6] and Vercammen et
al. [16] who both reported that IgG anti-Leishmania titers
increased significantly in symptomatic dogs when compared
to an asymptomatic control group.
During CanL overproduction of IgG, IgM and IgA,
consequent to B cell activation, causes the formation of
immuno-complexes [17].
Immunomediated mechanisms have a pivotal role in
the development of renal pathology [18], and immunocom-
plex deposition in glomeruli is the cause of four princi-
pal types of glomerulonephritis: focal or diffuse mesangial
glomerulonephritis,membranous glomerulonephritis,mem-
branoproliferative glomerulonephritis, and focal segmental
glomerulosclerosis [19]. There is strong evidence that pro-
teinuria is a risk factor for the development and progression
of renal failure and that renal disease is the most severe
complication of CanL and is a sign of poor prognosis [20].
For these reasons, we have correlated the value of creatinine
and UP/UC with the IFAT titer to assess whether there was
an association between renal function analyses and the anti-
Leishmania antibodies (IgG).
Higher UP/UC mean value has been reported in dogs
with IFAT titers of 1 : 1280 and significant association between
UP/UC and IFAT (푃 = 0.004) but not between IFAT titer
and creatinine was observed (Table 3). Our results are in
accordance with Poli et al. [21] who, in a study of glomerular
lesions in dog with CanL, found no correlation between
renal involvement and anti-Leishmania titer and creatinine
but found correlation between glomerular lesions and the
amount of proteinuria. Glomerulopathy that characterized
CanL causes proteinuria due to deposition of circulating anti-
gen/antibody complexes; this factmay explain the correlation
betweenUP/UC and IgG value found in our study [18]. Renal
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damage with less than 75 percent of nonfunctional nephrons
may not cause increase of serum creatinine concentration
[22]; therefore, elevation of this parameter during CanL may
show up later than the presence of protein in the urine.This
may justify the lack of correlation between IFAT titer and
creatinine serum concentration found in our study.
5. Conclusions
In conclusion, our results show that dogs with the high-
est IFAT titers recorded had higher mean clinical scores
indicating a positive relationship (푃 < 0.0001) between
anti-Leishmania antibodies (IgG) and clinical manifestations
that becomes more evident in polisymptomatic subjects.
Significant correlation was found between IFAT titers and
urinary UP/UC.
The results of this study may help to clarify whether IFAT
titers could be usefully included in the short-term followup
of dogs with CanL. Results from the present study support
the idea that high IFAT titers are related with the presence of
multiple clinical symptoms suggesting a positive relationship
between IFAT titer and clinical manifestations.
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